BridgeBio Pharma Pre-Paid Expenses 2018-2024 | BBIO
BridgeBio Pharma pre-paid expenses from 2018 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
- BridgeBio Pharma pre-paid expenses for the quarter ending June 30, 2024 were $0.028B, a 38.21% increase year-over-year.
- BridgeBio Pharma pre-paid expenses for 2023 were $0.024B, a 10.87% increase from 2022.
- BridgeBio Pharma pre-paid expenses for 2022 were $0.022B, a 32.06% decline from 2021.
- BridgeBio Pharma pre-paid expenses for 2021 were $0.032B, a 9.69% decline from 2020.
BridgeBio Pharma Annual Pre-Paid Expenses
(Millions of US $) |
| 2023 |
$24 |
| 2022 |
$22 |
| 2021 |
$32 |
| 2020 |
$36 |
| 2019 |
$20 |
| 2018 |
$9 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Pre-Paid Expenses
(Millions of US $) |
| 2024-06-30 |
$28 |
| 2024-03-31 |
$28 |
| 2023-12-31 |
$24 |
| 2023-09-30 |
$23 |
| 2023-06-30 |
$21 |
| 2023-03-31 |
$25 |
| 2022-12-31 |
$22 |
| 2022-09-30 |
$26 |
| 2022-06-30 |
$33 |
| 2022-03-31 |
$34 |
| 2021-12-31 |
$32 |
| 2021-09-30 |
$32 |
| 2021-06-30 |
$27 |
| 2021-03-31 |
$26 |
| 2020-12-31 |
$36 |
| 2020-09-30 |
$27 |
| 2020-06-30 |
$21 |
| 2020-03-31 |
$20 |
| 2019-12-31 |
$20 |
| 2019-09-30 |
$22 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.045B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
